Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
  • Resources
    • 2023 Diversity, Equity, & Inclusion Report
    • 2023 Industry Snapshot
    • 2022 Massachusetts Biopharma Funding Report
    • 2022 MA Life Sciences Workforce Analysis Report
    • Economic Development
    • Biopharma Startup Toolkit
    • Career Center
    • MassBioEd
  • Events
    • Events Calendar
    • Overview of Events
    • Get Involved
  • Membership
    • Member Directory
    • Benefits of Membership
    • Savings and Rewards
    • Member News
    • Become a Member
    • Member Rates
    • Pay Company Dues
  • Savings & Rewards
    • MassBioEdge
  • Conference Center
    • MassBioHub
  • Programs
    • Bioversity at Southline Boston
    • State of Possible 2025 Report
    • Diversity, Equity, and Inclusion
    • Policy & Advocacy
    • Partnering Opportunities
    • MassBioDrive
    • Digital Health
    • BioReady Communities
  • About Us
    • About Us
    • News & Thought Leadership
    • Sponsorship Opportunities
    • Staff
    • Board of Directors
    • FAQs
    • Contact Us
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
Open search form

Member Directory

Click to Open Main Menu

Adept Therapeutics Inc.

Life Sciences | Drug Development
Beverly, MA 9787208161 Website

Overview

Adept Therapeutics Inc. (AdeptTx) is an innovative start-up biotech company located at Beverly and Woburn in Great Boston area, MA, with passion and commitment to discover and develop potentially life-changing medicines for people with unmet medical needs. Focusing on T cells, Natural Killer cells and immune-suppressive myeloid cells, we leverage multiple advanced antibody technologies to discover fully human or humanized antibody therapeutics to enhance anti-tumor immunity. We are establishing and optimizing two unique platforms including immune cell engager bispecific antibodies and multi-functional tri-specific antibodies, which change tumor microenvironment (TME) to boost immune responses against cancer cells through 1) recruiting and activating effector immune cells and 2) modulating immune-suppressive TME to support tumor killing effector cell function. Our expertise in GPCR antibody discovery and development enable us to reach for the “high-hanging fruits”, the most challenging targets for antibody therapeutics discovery . Our broad product portfolio focuses on both hematological malignancies, such as cutaneous lymphoma, and solid tumors including triple negative breast cancer, ovarian, colon, kidney, renal,prostate, and pancreatic cancers etc.

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • Contact
  • Privacy Policy
  • Fulfillment Policy
  • © 2024 All Rights Reserved